米氮平对2型糖尿病患者合并抑郁症的疗效观察

Effect of mirtazpine on type2diabetes mellitus patients with depression

目的探讨米氮平对2型糖尿病患者合并抑郁症的疗效。方法将120例合并抑郁症的2型糖尿病患者，随机分为研究组和对照组，每组60例。对照组仅用降糖药治疗，研究组在常规降糖药治疗基础上联用米氮平（15～45mg／d）治疗，治疗8周。在治疗前和治疗8周末均进行汉密尔顿抑郁量表（HAMD）评定和空腹血糖、餐后2h血糖、糖化血红蛋白（HbAlc）水平测定。结果经治疗8周后，两组抑郁症状、空腹血糖、餐后2h血糖、HbAlc水平均较治疗前显著下降，但研究组比对照组改善更明显，两组比较有统计学意义（P〈0．01或P〈0．05）。结论米氮平能明显改善2型糖尿病患者的抑郁症状，更有利于患者血糖的控制。

Objective To investigate the efficacy of mirtazpine for treating type 2 diabetes mellitus （DM） patients with depression. Methods A total of 120 type 2 DM patients with depression were randomly divided into control group and study group. Control group was only given hypoglycemic agent, and study group was given both hypoglycemic agent and mirtazpine （15 -45 rag/d） for the treatment of 8 weeks. All patients were assessed withHamilton Rating Scale for Depression （ HAMD ）, fasting blood glucose, 2 - hour postprandial blood glucose, glycated hemoglobin （HbAlc） in the baseline and after eight weeks of treatment. Results Both groups, patients in baseline and after treatment for 8 weeks had significantly improved in both depressive symptoms and the glycemic control, but the patients in study group were significantly superior to the control group （ P 〈 0. 01 or P 〈 0. 05）. Conclusion Mirtazpine is effective not only for controlling depressive symptoms, but also for improving the controlling of blood glucose in patients type 2 diabetes mellitus with depression.